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Preface
In September 2003, the Open Society Institute’s Public Health Programs and RESULTS Educa-
tional Fund undertook a study of the 14 countries targeted by President Bush’s Emergency Plan
for AIDS Relief. The purpose was to assess the TB needs of the 14 countries and highlight the
links between TB and HIV/AIDS in these countries. The methodology used to obtain data on the
14 countries included the following:
E Review and analysis of the WHO Report 2003, Global Tuberculosis Control: Surveillance, Plan-
ning, Financing, for 7 of the 14 countries included in the WHO report
E Review and analysis of additional WHO data, reports, and articles
E Telephone and email correspondence with staff from the Stop TB Partnership, World
Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), Pan-
American Health Organization (PAHO), Global Fund to Fight AIDS, Tuberculosis and
Malaria (GFATM), and managers of national TB control programs in Côte d’Ivoire,
Namibia, Rwanda, and Zambia
The Open Society Institute funded this report. Gaurav Bhattacharya, a consultant to RESULTS
Educational Fund, carried out the study and prepared the initial draft. Further research was con-
ducted by Sue Perez. Final drafting of the report was completed by Sue Perez and Joanne Carter
of RESULTS Educational Fund. Additional editing was provided by Thomas Pierce, and by Ari
Korpivaara and Jeff Hoover of the Open Society Institute’s communications office.
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Note on Cost Estimates
Cost estimates provided in this report estimate additional annual costs of: 1) treating active TB
in all HIV-positive individuals using the DOTS strategy in the 14 PEPFAR countries; and 2) treat-
ing all patients with active TB using the DOTS strategy in the 14 PEPFAR countries. An estimate
of $200 per TB case to detect TB and provide treatment under DOTS is used for 11 of the 14 coun-
tries. Per case cost estimates for Botswana, Namibia, and South Africa are higher due to their
status as lower middle-income countries. These estimates of the additional costs required would
allow for accelerated expansion of DOTS services in the initial years (through improving cure
rates and increasing detection of those sick with TB) and then ongoing delivery of treatment.
These estimates are based on expanding services to those TB patients not currently treated under
DOTS programs. However, this is still a conservative estimate of the additional need because of
the costs associated with upgrading non-DOTS programs to the DOTS strategy and because the
$200 estimated cost per case is based on normative data (while empirical data shows that the
cost per case to treat TB can be higher).
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Executive Summary
The global HIV/AIDS epidemic has reached staggering proportions. UNAIDS estimated that in
2003 some 40 million people worldwide were living with HIV/AIDS and over 3 million died.
While the global response to HIV/AIDS is growing, too little attention is being paid to the rela-
tionship between HIV/AIDS and tuberculosis. 
These two diseases are inextricably linked. As rates of HIV/AIDS have risen, TB rates have
also skyrocketed. An estimated 2 billion people worldwide are infected with the TB bacterium,
although the vast majority never become sick or show any symptoms. But especially for people
with compromised immune systems, TB can be deadly. TB is the most common opportunistic
infection and number one cause of death for people with HIV/AIDS. The good news is that treat-
ing TB is one of the most effective means of improving and prolonging the lives of people with
HIV/AIDS and those who care for them. Curing TB in those dually infected can extend their lives
by two to five years. 
In his 2003 State of the Union Address, President Bush pledged $15 billion over five years
to fight the HIV/AIDS pandemic. A significant portion of this funding will go to an initiative
known as the President’s Emergency Plan for AIDS Relief (PEPFAR), which will prioritize efforts
in 14 highly affected African and Caribbean countries. The PEPFAR initiative offers a singular
opportunity to focus U.S. bilateral funds to make a significant impact in these countries. What-
ever lessons are learned will inform future efforts elsewhere. Most notably, it will be the first
large-scale effort by the U.S. government to treat people living with HIV/AIDS.
The PEPFAR initiative would be well served to ensure that from the earliest
planning stages efforts to combat both HIV/AIDS and TB are integrated.
There is no way to address effectively the HIV/AIDS epidemic without 
scaling up efforts to combat tuberculosis.
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This paper surveys the current state of HIV/TB coinfection in each of the 14 target coun-
tries. It outlines the benefits of better integrating TB and HIV/AIDS efforts by expanding TB pro-
grams to reach all those HIV patients with TB and linking TB programs to HIV/AIDS voluntary
counseling and testing (VCT). It also calls on the U.S. government to lead efforts to ensure a
robust response not only to the HIV/AIDS epidemic, but also to the TB/HIV coepidemic. 
The PEPFAR initiative would be well served to ensure that from the earliest planning stages
efforts to combat both HIV/AIDS and TB are integrated. There is no way to address effectively the
HIV/AIDS epidemic without scaling up efforts to combat tuberculosis. Nevertheless, to date,
global efforts to combat the two epidemics have largely proceeded on separate tracks. In resource-
poor settings, this places an unnecessary burden on the health care system. It also has a nega-
tive impact on patient care, since in most of the target countries more than one-third of TB
patients are also infected with HIV/AIDS.
The course of action is clear. The U.S. government must work with other donors, multi-
lateral organizations, and community-based organizations to do the following: 
E Expand the DOTS (Directly Observed Treatment, Short-course) strategy for curing stan-
dard TB to all TB/HIV-infected individuals, and provide prophylactic treatment for latent
TB to all persons living with HIV
E Integrate DOTS TB treatment and HIV voluntary counseling and testing
E Prioritize the development of new TB diagnostics and drugs for coinfected individuals in
order to improve the speed and effectiveness of diagnosis and to significantly reduce treat-
ment time and interactions between anti-TB drugs and ARVs 
E Support the Global TB Drug Facility to continue providing low-cost anti-TB drugs to coun-
tries in need 
Global leadership on TB/HIV coinfection is urgently needed from the new U.S. Office of
the Global AIDS Coordinator. On February 23, 2004, the Bush administration released its ini-
tial five-year global HIV/AIDS strategy. Unfortunately, the strategy does not give sufficient atten-
tion to the TB/HIV copandemic. It fails to address the ways in which HIV/AIDS prevention, care,
and treatment can benefit from integration with TB programs. Both USAID and NIH recognize
the urgency of addressing TB and HIV together. The president’s plan, however, has yet to allo-
cate adequate funding to enable this to occur. 
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A Critical Opportunity
The new U.S. Office of the Global AIDS Coordinator and Congress have a critical opportunity to
realize the promise of the President’s Emergency Plan for AIDS Relief (PEPFAR) by establish-
ing program and budgetary strategies that integrate efforts to prevent and treat HIV/AIDS with
efforts to control tuberculosis. Expanding effective TB treatment will extend the lives and improve
the quality of life for people living with HIV/AIDS and help achieve the bold AIDS treatment goals
within the PEPFAR initiative.
In his 2003 State of the Union Address, President Bush announced his proposal for PEP-
FAR, a $15 billion, five-year initiative from 2004 to 2008 that would focus, in particular, on 14
countries in Africa and the Caribbean that are highly affected by AIDS: Botswana, Côte d’Ivoire,
Ethiopia, Guyana, Haiti, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanza-
nia, Uganda, and Zambia. 
In the summer of 2003, Congress passed authorizing legislation—the United States Lead-
ership Act Against HIV/AIDS, Tuberculosis and Malaria. Signed into law by the president, this
bill sets priorities for the prevention, treatment, and care of people with HIV/AIDS, including the
provision of antiretroviral therapies. The bill established the Office of the Global AIDS Coordi-
nator to oversee the U.S. government’s expanded AIDS initiatives. A 15th country will be added
to the original list of 14 to be targeted by PEPFAR.
The bill also authorized funding for TB and malaria. For TB, the legislation aims to expand
access to the DOTS treatment strategy for TB and DOTS-Plus for treating cases of multi-drug
resistant TB.1
A person with HIV/AIDS in a developing country who contracts active 
TB has an estimated average survival time of several weeks. With effective 
TB treatment, survival time can be extended significantly 
by two to five years.
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PEPFAR’s specific targets for HIV/AIDS include the prevention of 7 million new HIV infec-
tions; the treatment of 2 million HIV-infected people; and the care of 10 million HIV-infected
individuals and AIDS orphans.
Without a strategy that includes TB, these goals for HIV/AIDS will be nearly impossible
to achieve. 
The Deadly Synergy Between TB and HIV/AIDS
In addressing the HIV/AIDS pandemic, TB is far too often ignored or viewed as just one of many
opportunistic infections. In fact, TB is the leading killer of people with HIV/AIDS and the first
presenting sign in the majority of AIDS patients. It is estimated that about one-third of people
with HIV are also infected with TB. Up to half of those living with HIV will develop TB in their
lifetime. 
One in three people worldwide carries the TB bacterium in the form of a latent infection.
HIV/AIDS weakens the immune system, and HIV infection increases by some 800-fold the like-
lihood that a person will develop active TB, which is usually fatal if not treated. There is also
significant evidence that TB accelerates the progression of HIV infection. A person with HIV/AIDS
in a developing country who contracts active TB has an estimated average survival time of sev-
eral weeks. With effective TB treatment, survival time can be extended significantly by two to five
years.2
Sub-Saharan Africa has the highest rates of TB, as well as HIV/AIDS, globally. Today, almost
70 percent of those coinfected with TB and HIV live in Africa. High rates of HIV have caused
TB rates to skyrocket. For example, in Kenya, the number of new TB cases is increasing at the
alarming rate of 12 percent each year.3 In Côte d’Ivoire, Ethiopia, Mozambique, Namibia, Nige-
ria, Rwanda, and South Africa, the rate is increasing at 7 percent annually.4 This is in contrast
to a global annual rate of increase in TB of just 0.4 percent.5 In the Latin America and Caribbean
region, Haiti stands out as the country with the highest rates of HIV/AIDS and TB/HIV coinfec-
tion. Globally, HIV/AIDS is the single most important factor fueling the increasing incidence of
TB over the last decade.
While TB works in deadly synergy with HIV/AIDS to take advantage of those with weakened
immune systems, TB is far more than just an opportunistic infection. TB is an airborne infectious
disease that kills 2 million people a year (the majority of whom are HIV negative), making it the
greatest curable infectious killer on the planet. This has significant implications for public health
in regions with high levels of HIV and TB, and for the global community. A person with active
TB has been estimated to spread the disease to some 15 other people in a year even in low HIV
prevalence settings. TB is a growing global epidemic to which we are all vulnerable.
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The TB/HIV Coepidemics in the PEPFAR Countries
This report focused on the TB/HIV coepidemic in the 14 countries identified by the PEPFAR ini-
tiative. Some of the findings also apply to other countries. From the data presented, it is clear
that all of the 14 countries targeted in the president’s plan suffer greatly from epidemics of TB
and HIV/AIDS, and that the synergy between the two diseases has caused TB rates to skyrocket. 
TB incidence rates among the highest in the world
Globally, the average annual rate of TB incidence is estimated at 138 new cases per 100,000 pop-
ulation.6 (In the United States in 2002, there were 5.2 new cases of TB per 100,000.7 ) The inci-
dence rates in the 14 countries (with the exception of Guyana) were more than 2 to 5 times the
global average (and up to 144 times higher than the United States). 
E Seven of the 14 target countries—Ethiopia, Kenya, Mozambique, Nigeria, South Africa,
Tanzania, and Uganda—have been identified by the WHO as among the 22 countries with
the highest TB burden in the world.8
Data also show that these countries need to make significant progress in expanding access
to effective TB treatment if the WHO 2005 TB targets are to be met. While the WHO target is to
detect at least 70 percent of new TB cases under DOTS by 2005, the average case detection rate
of the 14 countries is currently just slightly above 44 percent. Eventually countries should be
detecting and treating all active cases of TB. The WHO target for curing those detected is 85 per-
cent. Thus far, the target has been achieved by only one country—Guyana. 
E Overall, only 41 percent of all active TB cases are being detected and treated under DOTS
in these countries. Over 925,000 people with active TB have not yet been reached by DOTS
programs. 
E Detection of new active TB cases has decreased in nine countries since 1998.
TB incidence rates continuing to rise 
The incidence rate of TB has been rising much faster in sub-Saharan Africa than in the rest of
the world. Globally, the incidence of TB is increasing at an annual rate of only 0.4 percent.9 In
the 14 countries, the average annual increase in incidence is over 5 percent. In the last decade
and a half, several of the target countries have seen more than a five-fold increase in TB rates. 
E 13 of the 14 countries have experienced large annual increases in TB incidence since
1997—increases of 3 percent or more. The highest annual increase in incidence was in
Kenya—at 12 percent.10
E The rise in tuberculosis incidence is particularly profound in eastern and southern Africa,
regions hardest hit by HIV/AIDS.11
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High rates of TB/HIV coinfection
E By conservative estimates, there are over 435,000 HIV-infected individuals with active TB
in the 14 countries.12
E In Namibia, South Africa, and Zambia, at least 60 percent of adults with active TB are also
HIV positive. In Botswana, the rate of HIV infection in those diagnosed with TB is 79 per-
cent. Guyana has the lowest coinfection rate at 14 percent.13
E Fewer than half of HIV-positive TB patients were detected and treated under DOTS pro-
grams in these countries, leaving over 222,000 coinfected individuals not reached by
DOTS programs.
The majority of the 14 countries do not have comprehensive and coordinated TB-HIV/AIDS
strategies. 
The Urgent Need to Address TB and HIV Together
In most countries with HIV/AIDS epidemics, TB and HIV/AIDS are still addressed as separate and
distinct diseases, and HIV/AIDS control strategies too often ignore TB. Despite a cure for TB that
is effective in people also infected with HIV, in 2003 the WHO estimated that 70 percent of coin-
fected people in sub-Saharan Africa did not have access to low-cost anti-TB drugs. 
The WHO-recommended strategy to cure standard TB is DOTS. DOTS combines five ele-
ments—political commitment, microscopy services, drug supplies, surveillance and monitoring
systems, and use of highly efficacious treatment regimes, including chemotherapy. Once the
patients with infectious TB have been identified, health and community workers and trained vol-
unteers observe and record patients swallowing the full course of the correct dosage of anti-TB
medicines. The drugs required for a full six to eight months of standard treatment under DOTS
cost as little as $10. Effective strategies also exist for treating multi-drug resistant TB—DOTS-
Plus, built upon the DOTS model. The WHO’s Green Light Committee has reduced the cost of
second-line TB drugs by as much as 90 percent.
The example of India’s Revised National TB Control Program (RNTCP) shows the remark-
able progress that is possible for rapidly scaling up TB efforts. India’s RNTCP has expanded
India’s DOTS coverage 40-fold in the last five years to over 70 percent of the country’s popula-
tion. To date, the RNTCP has successfully treated 2.5 million TB patients and trained 300,000
health workers. The TB cure rate under the RNCTP DOTS program is 84 percent. The Stop TB
Partnership, an international coalition of over 300 institutions, is using the India model and pro-
viding increased support for more rapid scale-up in priority countries with high burdens of TB
and/or TB/HIV through a new initiative called “Intensified Support & Action Countries” (ISAC). 
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An Existing Infrastructure to Expand Programs to
Address Coinfection
Successful programs to control TB exist. Utilizing the TB-control infrastructure, promising efforts
to treat TB/HIV coinfection are underway. The United States should support these programs and
use their experiences with TB/HIV coinfection to inform PEPFAR’s efforts.
The Global TB Drug Facility
The Global TB Drug Facility (GDF) is a remarkably successful mechanism—a “virtual” facility,
designed to increase access to high-quality anti-TB drugs. In operation since 2001, the GDF is a
model program that allows countries to apply for supplies of first-line anti-TB drugs. To date, the
GDF has succeeded in reducing the price of the drugs for a standard six-month course of TB treat-
ment to just $10, and has approved over 40 countries to receive these low-cost anti-TB drugs. 
Despite its remarkable effectiveness, the GDF is facing a serious funding crisis. It does not
have monies pledged to meet existing commitments in 2004 and 2005 or to make any new
grants for drug purchases. If the GDF does not get its minimum needed funding, almost 1 mil-
lion TB patients will be put at serious risk and many could die, and supplies of drugs will be
interrupted—creating the perfect conditions to develop dangerous multi-drug resistant TB. The
GDF needs an estimated $50 million annually to allow maximum impact. The U.S. government
to date has provided just $2 million to the GDF in 2002 and $3 million in 2003. An annual U.S.
investment of $15 million in the GDF could treat over 1 million TB patients.
Stop TB Partnership
The Stop TB Partnership, an international coalition of over 300 institutions with its secretariat
housed at the WHO, leads a global movement committed to social and political action to stop the
unnecessary spread of tuberculosis around the world. The mission of Stop TB is to stop the trans-
mission of TB, to ensure that those people already infected with TB receive proper treatment and
have access to the cure, and to reduce both the social and economic impact that TB has on fam-
ilies, communities, and nations. 
The Stop TB Partnership, established in 1998, is represented by governments of the high-
burden TB countries and over 100 country partners, donors, international groups, and NGOs
committed to eliminating TB.
Global TB/HIV Working Group
Under the umbrella of the Stop TB Partnership, there are six working groups that provide a focus
for coordinated action on specific TB issues, including one on DOTS expansion, two addressing
the new threats of TB/HIV and multi-drug resistant TB, and three working on development of new
tools—drugs, diagnostics, and vaccines. The Global TB/HIV Working Group is especially relevant
in the context of this report because it works to coordinate the response to the closely linked HIV
and TB epidemics by building cooperation between the HIV/AIDS and TB communities.
         
1 4 I N T E G R A T I N G  H I V / A I D S  A N D  T B  E F F O R T S
As a result of the work of the Global TB/HIV Working Group, the World Health Organi-
zation released its Interim Policy on Collaborative TB/HIV Activities in January 2004. This docu-
ment is intended to aid policymakers in understanding what should be done to reduce the double
burden of TB and HIV. It is designed to be used in conjunction with the WHO’s 2002 report,
Strategic Framework to Decrease the Burden of TB/HIV, and its 2003 report, Guidelines for Imple-
menting Collaborative TB and HIV Programme Activities. 
Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)
The Global Fund to Fight AIDS, Tuberculosis and Malaria, founded in April 2001, is a public-pri-
vate partnership that was created to finance the massive scale-up of effective efforts to combat
AIDS, TB, and malaria through prevention, treatment, and care. To apply for GFATM resources,
countries create country coordinating mechanisms (CCMs) with representatives from both the
public and private sectors, including governments, multilateral or bilateral agencies, non-
governmental organizations, academic institutions, private businesses, and people living with
the diseases. CCMs develop and submit grant proposals to the GFATM, which are reviewed by a
global technical review panel that makes recommendations to the board. After grant approval,
the GFATM oversees and reviews progress and the use of funds. 
To date, the GFATM has approved grants totaling over $2.1 billion to 121 countries. Of the
total amount pledged, approximately $319 million, or 6 percent, was approved for joint TB/HIV
country projects, with 60 percent overall pledged for HIV/AIDS programs and 17 percent for TB. 
The U.S. contribution to the GFATM in 2003 was $350 million. The 2004 contribution
could be as much as $550 million, depending on the availability of matching funds. In 2005,
however, President Bush proposed only $200 million for the GFATM, which would cripple its
ability to expand much-needed programs.
Without an effective and integrated approach to TB and HIV/AIDS, millions of people with
HIV/AIDS will continue to die needlessly, deprived of existing TB treatments that could have pro-
longed their lives by years, even as HIV antiretroviral treatments are scaled up. Moreover, with-
out an integrated approach to the TB/HIV coepidemic, TB will spread to millions more
HIV-positive and -negative individuals. Controlling TB not only saves lives but also benefits those
caring for people living with AIDS—health care workers, family members, and others—by pro-
tecting them against potential TB infection. 
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Recommendations
The job of the U.S. Office of the Global AIDS Coordinator within the State Department is to coor-
dinate the U.S. government’s response to the global AIDS epidemic. Ambassador Randall Tobias
was sworn into that office on October 6, 2003.
The following are a series of broad policy recommendations addressing the major bene-
fits to people with HIV/AIDS of expanding TB treatment and improving TB and HIV/AIDS pro-
gram linkages in the 14 PEPFAR countries. Specific guidelines and recommendations for
implementing these and other TB/HIV efforts are provided in the Interim Policy on Collaborative
TB/HIV Activities, released by the WHO in January 2004, and the Guidelines for Implementing Col-
laborative TB and HIV Programme Activities, released by the WHO in 2003. 
The first two recommendations are administrative, the rest programmatic. The last rec-
ommendation is for the U.S. government in general.
The U.S. Office of the Global AIDS Coordinator should:
1. Appoint a senior official to focus on addressing TB/HIV coinfection
This individual could serve as a point of contact for external partners and donors and
ensure that appropriate technical assistance is delivered to the 14 countries. Specific actions
should include briefings for all relevant U.S. government staff—including staff in the target coun-
tries—on the TB/HIV situation and ensuring that plans are developed to coordinate TB and
HIV/AIDS programs for maximum impact.
DOTS treatment programs for tuberculosis can serve as a primary entry point
for identifying people who are HIV positive and eligible for antiretroviral
treatment. Voluntary counseling and testing for HIV/AIDS should be
integrated into expanded DOTS programs.
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2. Establish coordinating bodies for TB/HIV in the 14 target countries
The Office of the Global AIDS Coordinator should work with the WHO to establish coor-
dinating bodies in the 14 target countries to carry out joint planning and resource mobilization
for HIV/TB. These bodies should build on the country coordinating mechanisms (CCMs) of the
Global Fund to Fight AIDS, Tuberculosis and Malaria. 
3. Expand DOTS to reach all HIV-infected individuals
In the context of HIV/AIDS, expanding access to DOTS TB treatment in the 14 target coun-
tries is essential in order to meet the president’s goals for treatment, prevention, and care.
Expanding DOTS to provide treatment to all patients with active TB who are HIV positive would:
E prolong the life span and improve overall quality of life for over 222,000 additional HIV-
infected individuals sick with TB;
E reduce the spread of TB among people with HIV/AIDS who are most vulnerable to devel-
oping active TB disease; and 
E prevent new TB infections in hundreds of thousands of others who are HIV negative, 
particularly those at greater risk (including health care workers, caretakers, and family
members of people with HIV/AIDS and TB), and the general population.
In the 14 PEPFAR countries, DOTS programs are currently detecting and treating about
213,000 TB patients who are HIV positive (Table 1), which represents less than half of coinfected
patients. An additional $53 million annually could detect and treat the remaining approximately
222,000 TB patients who are HIV positive using the DOTS strategy. This funding estimate rep-
resents costs for anti-TB drugs and DOTS treatment for HIV-positive patients not yet being
detected and treated under DOTS—as part of overall DOTS expansion. 
Country programs should be monitored and evaluated on their success in increasing detec-
tion and treatment under DOTS of TB in HIV-infected individuals.
4. Integrate DOTS and VCT
The PEPFAR targets are to treat 500,000 people with HIV/AIDS in 2004 and 2 million by
2008. A major challenge is to identify people who are HIV positive and who are candidates for
antiretroviral treatment. In nearly all of the PEPFAR countries, DOTS treatment programs can
serve as a primary entry point to identify people eligible for ARV treatment. Integrating expanded
DOTS programs with voluntary counseling and testing (VCT) for HIV/AIDS has additional bene-
fits in terms of preventing HIV infection. 
E Identify Candidates for ARV Treatment: The approximately 213,000 HIV-infected TB patients
detected and being treated for TB under DOTS (Table 1) represent less than half of the
estimated HIV-positive individuals with active TB in the 14 countries. Expanding DOTS
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treatment programs to reach all HIV-positive people with active TB, and linking TB patients
to VCT programs could identify over 435,000 HIV-infected individuals annually who would
be potential candidates for ARV treatment.
E Help prevent new HIV infections: Providing voluntary counseling and testing for HIV/AIDS
to TB patients offers patients an entry point into the continuum of care, support, and treat-
ment for HIV/AIDS. Access to VCT will help reduce the spread of HIV/AIDS by making
patients aware of their HIV status. All TB patients should also be introduced to HIV/AIDS
prevention methods.
Based on the WHO’s estimates, an additional $58.2 million will be needed annually to
effectively integrate VCT into DOTS programs in the 14 PEPFAR countries.14 This includes the
cost of HIV VCT for all patients detected with TB, and strengthened coordination between TB and
HIV/AIDS programs, including referral linkages. 
In some cases there may also be opportunities for combining actual delivery efforts of
ARVs and anti-TB drugs. Standard TB treatment—DOTS—involves taking a combination of anti-
TB drugs under the regular observation and support of a trained health worker or community
volunteer for six to eight months. DOTS can provide a model for ARV delivery, and in some cases
there may be opportunities for joint delivery efforts of ARVs and anti-TB drugs. 
Country programs should be monitored and evaluated on their success ensuring TB
patients are linked to VCT for HIV/AIDS, and ensuring all other appropriate linkages are in place
between TB and HIV/AIDS programs. 
5. Provide prophylactic TB treatment to people with HIV/AIDS who have latent TB
infection
Routinely screening people with HIV/AIDS for TB infection will help prolong people’s lives.
People with HIV are particularly vulnerable to reactivation of latent TB infections; providing pro-
phylactic anti-TB treatment with isoniazid can prevent the development of active TB disease in
those with HIV. This can protect and prolong people’s lives. In addition, the availability of pre-
ventive therapy is an added incentive for people to seek voluntary counseling and testing for
HIV/AIDS even before ARV treatment is widely available.
6. Prioritize the development of new diagnostic tools and treatment for TB in HIV-
infected individuals
Better TB diagnostic tools and anti-TB drugs are needed to increase efficiency of diagno-
sis and treatment of coinfected people. People with HIV/AIDS who have TB are more likely to
be missed by common diagnostic methods used to detect both active TB disease and latent TB
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infection. For this reason, new and better diagnostic methods are particularly important in
regions with high levels of TB/HIV coinfection. Also, certain widely used standard TB drugs inter-
act with ARVs. New TB drugs that avoid such interactions and shorten treatment time are criti-
cal, and would be particularly beneficial for those with HIV/AIDS.
Research and development efforts—including those being undertaken by the Global
Alliance for TB Drug Development to bring forward new and better anti-TB drugs, as well as
efforts to develop improved diagnostic tools—should receive expanded support.
7. Work with other donors and international organizations to treat all active TB cases
in the PEPFAR priority countries
In the 14 PEPFAR countries, annual incidence of TB is estimated at 1.574 million new TB
cases each year, with only about 41 percent (648,500) detected by DOTS programs (Table 2). This
leaves about 926,000 TB patients annually who are currently not being detected and treated
under DOTS programs. The total estimated cost to treat all active TB cases in the 14 PEPFAR coun-
tries would be $205 million annually (from all sources).
Expanding DOTS programs to treat all active TB cases would protect both HIV-positive and
HIV-negative members of the community, all of whom are at risk of contracting TB. 
The U.S. government should:
8. Increase its investment in global TB and TB/HIV control
The U.S. government should expand its investment to control TB globally and address
the growing coepidemic of TB/HIV, and work to mobilize other donors to do the same. Coun-
tries, including India and China, that are identified as the “next wave” of the HIV pandemic
already have massive TB epidemics.* Russia and Eastern Europe have among the fastest grow-
ing rates of HIV and the highest rates of MDR-TB in the world. In addition to what can and will
be achieved by PEPFAR in the 14 countries, increased investment in expanding TB treatment and
addressing TB/HIV worldwide and greater coordination of efforts among bilateral and multilat-
eral partners will be necessary to tackle these pandemics on a global scale.
* See September 2002 National Intelligence Council report at:
http://www.cia.gov/nic/PDF_GIF_otherprod/HIVAIDS/ICA_HIVAIDS20092302.pdf
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Conclusion
Expanding effective TB treatment programs in the 14 PEPFAR countries is an immediately avail-
able, high-impact means of keeping people with HIV/AIDS alive. Additionally, controlling the
TB epidemic protects communities. Expanding and strengthening the existing DOTS infra-
structure in the 14 countries selected to receive resources through PEPFAR, and linking these
programs to expanded voluntary counseling and testing services for HIV/AIDS, will provide the
most important entry point for identifying people with AIDS who are prime candidates for ARV
treatment. DOTS programs can provide important lessons and, in some cases, infrastructure
for scaling up ARV treatment activities. We cannot afford to treat TB and HIV as separate prob-
lems. By supporting expanded and strengthened programs and developing an integrated strat-
egy to tackle these diseases, we can save hundreds of thousands of additional lives and help
reverse this dual epidemic. 
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Country Profiles
The 14 key countries targeted in the President’s Emergency Plan for AIDS Relief are profiled in
the following pages. These country profiles include the most current statistics on TB (from 2002): 
1. Estimated number of new TB cases in that year
2. Overall TB incidence rate (number of new cases per 100,000 population)
3. Annual percentage increase in TB incidence (1997–2002)
4. Estimated number of TB deaths
5. Percentage of overall TB incidence occurring in adults aged 15 to 49 years
6. Percentage of adult TB cases with HIV coinfection
7. Percentage of TB deaths occurring in patients who were infected with HIV (Globally,
an average of 30 percent of HIV/AIDS cases are coinfected with TB. However, exact estimates
for each country of TB coinfection rates for HIV/AIDS cases are not available.)
8. Percentage of population “covered” by DOTS, i.e., percentage of TB services that are
implementing DOTS or Directly Observed Treatment, Short-course, the WHO-recommended
strategy for treating standard TB
9. Percentage of new TB cases actually detected and successfully cured under DOTS
programs
Each country profile also includes a brief summary highlighting significant information
on the TB and HIV/AIDS epidemics and TB/HIV coinfection, as well as trends in DOTS popula-
tion coverage, detection, and treatment success. 
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Botswana
CURRENT COUNTRY DATA ON TB (2002)
Population 1.770 million
Est. number of new TB cases 11,622
Overall TB incidence rate 657 per 100,000 population
Annual % increase in number of new TB cases 5.0 (1997–2002)
Est. number of TB deaths 1,593
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 79
% TB deaths that are HIV-infected 63
% DOTS population coverage 100
% DOTS detection (new smear+) 73
% DOTS treatment success (new smear+) 78 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
The huge HIV/AIDS problem in the country has undermined progress to control TB. Prevalence
of HIV/AIDS in Botswana is one of the highest in the world at almost 40 percent of the adult pop-
ulation living with HIV/AIDS.15 In conjunction with this very high prevalence of HIV/AIDS,
Botswana now also has the highest TB/HIV coinfection rate in sub-Saharan Africa—with over
three-quarters (79 percent) of adults who are newly diagnosed with TB estimated to also be
infected with HIV. 
In 2002, the annual incidence of TB had reached an alarming 657 new TB cases per
100,000 population—one of the highest in sub-Saharan Africa. To provide some perspective,
the global average TB incidence rate was 138 new TB cases per 100,000 population in 2001.16
In the United States, the average incidence rate for 2002 was 5.2 cases per 100,000 population
(making Botswana’s annual incidence 126 times the U.S. rate).17
Botswana’s estimate of 100 percent DOTS TB treatment coverage means that nearly all clin-
ics are providing DOTS treatment. The reported rate of successfully detecting 73 percent of new
cases of TB within DOTS programs is very good by global standards. However, further expand-
ing detection is critical, especially in a nation with such high rates of coinfection. In addition,
because HIV-positive patients are more likely to be missed by common DOTS detection meth-
ods, it is possible that the actual number of new TB cases is underestimated. 
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The massive rate of TB/HIV coinfection highlights the impact that effective TB treatment
will have on prolonging the lives of those with HIV/AIDS and the need to support comprehen-
sive and coordinated TB and HIV strategies. It also demonstrates the critical role that DOTS pro-
grams can and will play in identifying HIV-positive individuals who are in need of antiretroviral
treatment. 
Côte d’Ivoire
CURRENT COUNTRY DATA ON TB (2002)
Population 16.365 million
Est. number of new TB cases 67,376
Overall TB incidence rate 412 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 20,540
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 39
% TB deaths that are HIV-infected 44
% DOTS population coverage 74
% DOTS detection (new smear+) 25
% DOTS treatment success (new smear+) 73 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Ongoing political instability since a military coup in December 1999 has made it difficult for
the government of Côte d’Ivoire to address the country’s worsening TB and HIV/AIDS situation.
In the West Africa region, Côte d’Ivoire now has the highest adult prevalence rate of HIV/AIDS
at 9.7 percent.18 The TB-HIV/AIDS coinfection rate of 39 percent is also relatively high even among
the 14 PEPFAR countries. 
In 1998, an impressive 98 percent of TB clinics provided DOTS treatment. By 2001, DOTS
coverage had dropped dramatically to just 21 percent of the population—the lowest DOTS pop-
ulation coverage in Africa that year.19 In 2002, the government reported that 74 percent of TB
clinics were once again providing DOTS treatment. Actual detection of new TB cases under DOTS
has also followed an up and down trend over the last five years, from 51 percent in 1998 down
to a mere 9 percent in 2001.20 Currently, DOTS detection is slightly improved over 2001 to a level
of 25 percent, but it still has far to go. 
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Prior to 1999, Côte d’Ivoire had a DOTS program in place that covered most of the coun-
try. While the larger issue of political instability must be addressed, the Ivoirian experience of
providing the population access to DOTS can and should be built on as health care services are
restored. Given the levels of TB/HIV coinfection, a functioning TB program is particularly criti-
cal and can be a main entry point for scaling up HIV/AIDS treatment.
Ethiopia
CURRENT COUNTRY DATA ON TB (2002)
Population 68.961 million
Est. number of new TB cases 255,345
Overall TB incidence rate 370 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 60,938
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 29
% TB deaths that are HIV-infected 32
% DOTS population coverage 95
% DOTS detection (new smear+) 33
% DOTS treatment success (new smear+) 76 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
The estimated number of Ethiopians living with HIV/AIDS in 2001 was 2.1 million—5 percent
of the global total.21 In September 2002, the U.S. National Intelligence Council released The Next
Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India, and China, which predicted dramatic increases
in rates of HIV/AIDS in these five countries by 2010. The report estimates that the HIV/AIDS
epidemic will advance most rapidly in Nigeria and Ethiopia if the current priorities and focus
are not shifted to the growing problem in these countries. Already nearly one-third of adult TB
cases are HIV positive. As HIV/AIDS spreads, TB rates can be expected to skyrocket.
Out of the 22 high-burden TB countries identified by the WHO, Ethiopia ranks in the top
half, with some 255,300 new TB cases in 2002. Progress to control TB has been slow, with DOTS
coverage increasing by only 6 percent between 1998 and 2001.22 But then, between 2001 and
2002, the country reported that DOTS coverage increased to 95 percent. This means that nearly
all existing TB clinics now provide treatment under DOTS. However, detection of new TB cases
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stands at just 33 percent, far short of the WHO 2005 target of 70 percent. This slow progress,
in part, reflects the broader problem that nearly 50 percent of Ethiopia’s population does not
have access to primary health services overall and therefore little or no infrastructure exists to
expand DOTS or other services to much of the country.
Unless the low rate of detecting new TB cases is rapidly improved and DOTS and other
health services are extended, the rising rate of HIV/AIDS could cause the TB epidemic to spiral
out of control. One of the most immediate, effective ways to extend health services in Ethiopia
would be to expand DOTS coverage to the entire population. This could serve as a critical bridge
for scaling up of HIV/AIDS services and identifying candidates for antiretroviral treatment.
Guyana
CURRENT COUNTRY DATA ON TB (2002)
Population 763,722
Est. number of new TB cases 879
Overall TB incidence rate 115 per 100,000 population
Annual % increase in number of new TB cases 8.0 (1997–2002)
Est. number of TB deaths 166
% new TB cases in adults (15-49 yrs) 61
% Adult TB cases that are HIV+ 14
% TB deaths that are HIV-infected 15
% DOTS population coverage 25
% DOTS detection (new smear+) 11
% DOTS treatment success (new smear+) 90 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
A relatively small country with a population of less than one million, Guyana continues to be
seriously affected by HIV/AIDS. Out of the 20 Central and South American countries, Guyana
has one of the highest adult prevalence rates of HIV/AIDS—at almost 3 percent.23 The HIV/AIDS
epidemic has fueled increased rates of TB/HIV coinfection, which now stands at 14 percent—
second only to Haiti. 
Guyana’s TB incidence rate is one of the highest in the Latin American and Caribbean
region. Since 1997, Guyana has seen an 8 percent annual increase in the number of new TB
cases. This is not surprising given that Guyana has one of the lowest levels of DOTS treatment
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coverage in the entire region, with only 25 percent of people having access to DOTS treatment.
The number of TB cases actually detected under DOTS stands at an abysmally low 11 percent.
With support, Guyana should have the capacity to make rapid progress in expanding DOTS
coverage and to have a significant impact on its TB problem, even in the face of its HIV/AIDS epi-
demic. While a small percentage of people with TB are currently treated within DOTS programs,
their treatment success is very high. Every effort should be made to replicate these effective treat-
ment procedures as overall coverage and detection are expanded.
Haiti
CURRENT COUNTRY DATA ON TB (2002)
Population 8.218 million
Est. number of new TB cases 26,224
Overall TB incidence rate 319 per 100,000 population
Annual % increase in number of new TB cases -4.0 (1997–2002)
Est. number of TB deaths 5,895
% new TB cases in adults (15-49 yrs) 61
% Adult TB cases that are HIV+ 28
% TB deaths that are HIV-infected 29
% DOTS population coverage 45
% DOTS detection (new smear+) 41
% DOTS treatment success (new smear+) 75 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Among all countries in Latin America and the Caribbean, Haiti has the highest incidence and
prevalence rates of TB;24 highest rate of HIV/AIDS;25 and the highest TB/HIV coinfection rate.26 Less
than half of the population of 8.2 million people has access to DOTS TB treatment and only 41
percent of new TB cases are detected within DOTS programs every year. Decades of political insta-
bility and a lack of foreign aid and investment have helped sustain serious economic crises and
compromised the government’s ability to deal with its devastating TB and HIV/AIDS epidemics. 
Partners in Health is leading a highly successful effort, modeled on the DOTS strategy, to
integrate TB and HIV/AIDS treatment in rural areas of the country. Trained health workers deliver
not only TB treatment but also free antiretroviral medications to people with HIV/AIDS in their
homes, as well as provide other support services for patients.27 This integrated approach to
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addressing the dual epidemics of TB and HIV/AIDS can be applied to other parts of the country
and provides important lessons for global scale-up of ARV treatment.  
Kenya
CURRENT COUNTRY DATA ON TB (2002)
Population 31.540 million
Est. number of new TB cases 170,213
Overall TB incidence rate 540 per 100,000 population
Annual % increase in number of new TB cases 12 (1997–2002)
Est. number of TB deaths 41,648
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 51
% TB deaths that are HIV-infected 53
% DOTS population coverage 100
% DOTS detection (new smear+) 49
% DOTS treatment success (new smear+) 80 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
In Kenya, 15 percent of the population is living with HIV/AIDS—a number that represents 6
percent of the global total.28 Due to the significant TB and HIV/AIDS epidemics in the country,
the TB/HIV coinfection rate now stands at over 50 percent.
Kenya is classified by the WHO as one of the 22 high-burden TB countries. Kenya has expe-
rienced a sharp increase in the incidence of TB; the country’s annual increase in incidence rate
of 12 percent is among the highest in sub-Saharan Africa.
While Kenya estimates that all TB services are providing DOTS treatment, and treatment
success under DOTS is 80 percent (approaching the 2005 goal of 85 percent), much work
remains to increase the actual number of new cases being detected by DOTS programs—still less
than half of those sick with TB. Rapid progress toward ensuring that nearly all TB cases are actu-
ally detected and subsequently treated and cured within DOTS programs is critical, especially
with the alarmingly rapid increase in TB incidence.
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Mozambique
CURRENT COUNTRY DATA ON TB (2002)
Population 18.537 million
Est. number of new TB cases 80,893
Overall TB incidence rate 436 per 100,000 population
Annual % increase in number of new TB cases 7 (1997–2002)
Est. number of TB deaths 23,044
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 47
% TB deaths that are HIV-infected 51
% DOTS population coverage 100
% DOTS detection (new smear+) 45
% DOTS treatment success (new smear+) 77 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Mozambique’s adult HIV/AIDS prevalence rate of 13 percent is one of the highest in sub-Saha-
ran Africa.29 The level of TB/HIV coinfection is also one of the highest in the region at 47 per-
cent, and over half of all TB deaths were associated with HIV. 
Mozambique is among the WHO’s 22 high-burden TB countries, with almost 81,000 new
TB cases annually. Despite Mozambique reporting 100 percent DOTS coverage, it is estimated
that only about half of the population may actually have access to DOTS programs. The possi-
bility of an overreporting of DOTS coverage nationwide suggests that the actual number of new
cases of TB is higher than estimated. Moreover, a lower actual DOTS population coverage would
also suggest an overestimate of the percentage of new TB cases detected under DOTS. It is crit-
ical that Mozambique ensure that the entire population has access to DOTS and that DOTS pro-
grams work to improve detection of those sick with TB.
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Namibia
CURRENT COUNTRY DATA ON TB (2002)
Population 1.961 million
Est. number of new TB cases 14,724
Overall TB incidence rate 751 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 2,158
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 64
% TB deaths that are HIV-infected 53
% DOTS population coverage 60
% DOTS detection (new smear+) 77
% DOTS treatment success (new smear+) 63 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
In Namibia, adult prevalence of HIV/AIDS is 22.5 percent—the fourth highest in southern Africa.
Given that high rate, it is no surprise that TB/HIV coinfection is over 60 percent. 
Namibia suffers from one of the highest incidence rates of TB in sub-Saharan Africa at
751 new TB cases per 100,000 population—an increase over the incidence rate in 2001 of 626
cases per 100,000 population.30 The reported DOTS population coverage has stood at 60 percent
since 2001; however, case detection has declined from a level of 81 percent in 2001 to 77 percent
today.31 Such a decrease in case detection could be explained by the inaccessibility of clinics due
to large geographical distances between clinics and patients.
Despite the immense challenge of its TB and HIV/AIDS epidemics, Namibia has greater
capacity than many of its neighbors, and, with adequate support, it should be able to rapidly
expand and improve its national TB control program. This is urgent given the very high rate of
TB infection and TB/HIV coinfection.
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Nigeria
CURRENT COUNTRY DATA ON TB (2002)
Population 120.911 million
Est. number of new TB cases 367,836
Overall TB incidence rate 304 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 108,135
% new TB cases in adults (15-49 yrs) 65
% Adult TB cases that are HIV+ 27
% TB deaths that are HIV-infected 30
% DOTS population coverage 55
% DOTS detection (new smear+) 12
% DOTS treatment success (new smear+) 79 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Although Nigeria does not yet have the mature HIV/AIDS epidemic of many southern and east-
ern African countries, the sheer size of its overall population means that Nigeria had almost 9
percent (3.5 million people) of the estimated global total of people living with HIV/AIDS at the
end of 2001.32 Because Nigeria’s HIV/AIDS epidemic is less advanced, the TB/HIV coinfection
rate is lower than in many other countries, despite a large burden of TB. The September 2002
National Intelligence Council report, however, identified Nigeria as one of five “next wave” coun-
tries where HIV/AIDS is expected to spread rapidly by 2010, with immense social and economic
consequences predicted for Nigeria, in particular. 
As the most populous country in sub-Saharan Africa, Nigeria carries the largest number
of TB cases on the continent—about 367,800 cases in 2002. This high burden of TB has placed
it among the top five of the WHO’s 22 high-burden TB countries. In 2002, about 108,100 peo-
ple died of TB in Nigeria. Overall DOTS coverage is only 55 percent. Of even greater concern,
detection of new TB cases under DOTS is one of the lowest in sub-Saharan Africa at 12 percent,
a decrease from 2001 when it was 16 percent.33
Current government efforts to control both TB and HIV/AIDS will need to be ramped up
dramatically in order to avert greater disasters. Nigeria has a short window of opportunity to rap-
idly scale up DOTS TB control efforts before HIV/AIDS pushes TB rates higher and makes TB con-
trol much more difficult. In addition, with a current adult coinfection rate of 27 percent,
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expansion of DOTS programs can function as a key entry point for identifying those with
HIV/AIDS—in order to expand HIV prevention and AIDS treatment efforts. 
Rwanda
CURRENT COUNTRY DATA ON TB (2001)
Population 8.272 million
Est. number of new TB cases 32,155
Overall TB incidence rate 389 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 9,480
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 37
% TB deaths that are HIV-infected 43
% DOTS population coverage 100
% DOTS detection (new smear+) 29
% DOTS treatment success (new smear+) 61 (2000 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Civil war, massive population displacements, and political conflicts with neighboring countries
have left Rwanda in severe social and economic crisis. By the end of 2001, the estimated num-
ber of adults living with HIV/AIDS in Rwanda was nearly 9 percent of the population.34
The extent of the country’s social and economic deterioration is also partly reflected in
Rwanda’s TB program, where DOTS case detection and treatment success rates have both
decreased since 1998. Much of the country’s health infrastructure has deteriorated over the last
decade, and detection of new TB cases within DOTS programs fell from 58 to 29 percent of all
cases, and treatment success within DOTS programs fell from 72 to 61 percent.35 Another indi-
cator of Rwanda’s worsening TB situation is its annual increase in the number of new TB cases
since 1997. This 7 percent increase per year is one of the highest in sub-Saharan Africa.
Rwanda’s high rates of TB and HIV can be expected to rise further if the current political
situation does not improve. The TB/HIV coinfection rate stands at 37 percent—one of the high-
est in the region—demonstrating the importance of reversing the decline in TB control efforts
and the importance of expanding and strengthening DOTS programs as a main entry point for
scaling up HIV/AIDS efforts.
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South Africa
CURRENT COUNTRY DATA ON TB (2002)
Population 44.759 million
Est. number of new TB cases 249,660
Overall TB incidence rate 558 per 100,000 population
Annual % increase in number of new TB cases 7.0 (1997–2002)
Est. number of TB deaths 35,497
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 60
% TB deaths that are HIV-infected 60
% DOTS population coverage 98
% DOTS detection (new smear+) 96
% DOTS treatment success (new smear+) 65 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
South Africa is only beginning to address its huge HIV/AIDS epidemic. It is estimated that 20
percent of adults in South Africa were living with HIV/AIDS by the end of 2001.36 This represents
over 12 percent of the global total of people with HIV/AIDS.37 An estimated 60 percent of adults
with active TB are HIV positive.
In 2001, South Africa reported an estimated 243,306 new cases of TB, making it seventh
highest on the WHO’s list of 22 high-burden TB countries.38 (This number increased in 2002
to over 249,000 new TB cases.) South Africa has one of the highest rates of new TB cases in
the world, increasing at an annual rate of 7 percent between 1997 and 2002. The overall TB inci-
dence rate was 558 per 100,000 population in 2002. 
South Africa reports 98 percent DOTS coverage, meaning that nearly all TB clinics are treat-
ing patients under DOTS. The estimate of 96 percent actual detection of active TB cases under
DOTS is extremely high by global standards. Even if it represents an overestimate—it is likely
that both the overall incidence of TB has been underestimated in South Africa and that some TB
cases may be accidentally double-counted—this still implies good outreach. Of concern is the
relatively low rate of treatment success under DOTS—at just 65 percent, especially given the high
treatment cost per case in South Africa, which is over $700 per case for treatment in urban
centers and over $1,200 per case nationally. South Africa needs to improve the treatment suc-
cess of its TB program—ensuring that patients entering the system complete treatment and are
cured—and to lower the cost of treatment.
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Tanzania
CURRENT COUNTRY DATA ON TB (2002)
Population 36.276 million
Est. number of new TB cases 131,566
Overall TB incidence rate 363 per 100,000 population
Annual % increase in number of new TB cases 3.0 (1997–2002)
Est. number of TB deaths 29,789
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 34
% TB deaths that are HIV-infected 37
% DOTS population coverage 100
% DOTS detection (new smear+) 43
% DOTS treatment success (new smear+) 81 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Adult prevalence of HIV/AIDS stands at about 8 percent of the population.39 Furthermore, an esti-
mated 34 percent of adult TB cases are HIV positive. 
Tanzania is identified by the WHO as one of the 22 high-burden TB countries. Among
the 14 countries targeted in PEPFAR, Tanzania is surpassed only by Nigeria, South Africa,
Ethiopia, and Kenya in number of TB cases—with 131,566 new TB cases in 2002. While 
Tanzania estimates 100 percent DOTS population coverage, it should be of concern that the actual
detection of new TB cases under DOTS has decreased steadily since 1998 from 53 percent that
year to 43 percent in 2002 and is well below the WHO target of 70 percent case detection by
2005.40 A greater commitment to TB control by the Tanzanian government, particularly ensur-
ing increased case detection so that all of those sick with TB actually receive treatment, is needed
to turn this trend around.
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Uganda
CURRENT COUNTRY DATA ON TB (2002)
Population 25.004 million
Est. number of new TB cases 94,362
Overall TB incidence rate 377 per 100,000 population
Annual % increase in number of new TB cases 3.0 (1997–2002)
Est. number of TB deaths 21,392
% new TB cases in adults (15-49 yrs) 65
% Adult TB cases that are HIV+ 24
% TB deaths that are HIV-infected 26
% DOTS population coverage 100
% DOTS detection (new smear+) 47
% DOTS treatment success (new smear+) 56 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
While Uganda has been successful in slowing its HIV/AIDS epidemic, HIV/AIDS has been an
immense challenge to progress in efforts to control TB. An estimated 5 percent of the adult pop-
ulation is living with HIV.41 In addition, 24 percent of adults with TB are infected with HIV.
Uganda is one of the 22 high-burden TB countries identified by the WHO. In 2002, the
number of new TB cases was over 94,000, up from 78,000 in 2001.42 Case detection under DOTS
has decreased steadily from 61 percent in 1998 to 47 percent in 2002, well below the WHO 2005
target of 70 percent.43 Furthermore, the overall treatment success rate under DOTS stands at a
disappointing 56 percent.
Uganda, with the support of the United States and others, must increase the capacity of
its TB program to cure those patients who are in the system and to ensure that those with active
TB are actually accessing DOTS treatment. 
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Zambia
CURRENT COUNTRY DATA ON TB (2002)
Population 10.698 million
Est. number of new TB cases 71,509
Overall TB incidence rate 668 per 100,000 population
Annual % increase in number of new TB cases 3.0 (1997–2002)
Est. number of TB deaths 16,239
% new TB cases in adults (15-49 yrs) 71
% Adult TB cases that are HIV+ 62
% TB deaths that are HIV-infected 55
% DOTS population coverage 55
% DOTS detection (new smear+) 40
% DOTS treatment success (new smear+) 75 (2001 estimate)
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. 
CURRENT SITUATION
Zambia is one of the poorest countries in the world and has relatively high rates of TB and
HIV/AIDS. According to UNAIDS, about 21.5 percent of the adult population is living with
HIV/AIDS. As a result of this high rate, over 60 percent of adult TB cases are estimated to be
HIV positive.
Zambia has one of the highest TB incidence rates in sub-Saharan Africa, with 668 new
TB cases per 100,000 population in 2002—over five times the global average and 128 times that
of the United States in 2001.44 The country’s poverty and overall lack of basic health care serv-
ices were exacerbated by a disastrous World Bank–led health sector reform effort in the 1990s
that resulted in the dismantling of the existing TB control program. Efforts to rebuild the TB pro-
gram have been slow despite the urgent need. The government is just starting to report on the
status of DOTS coverage, detection, and treatment success. 
Zambia faces a particular challenge in rebuilding its dismantled TB control program in
the face of raging epidemics of TB and HIV/AIDS. However, given the enormously high rate of
TB and TB/HIV coinfection, action to expand DOTS treatment is urgent—to save lives now and
to provide the best means of identifying those with HIV/AIDS for scale-up of treatment and pre-
vention services. Unless Zambia receives massive assistance to address adequately its TB epi-
demic, as well as its HIV/AIDS epidemic, these two deadly diseases will continue to fuel each
other, causing more deaths and contributing to greater social and economic devastation.
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TABLE 1: Estimated Additional Annual Funding Required to Treat TB in Adult Cases 
(All Forms**) that are HIV-Positive (based on 2002 data)
# Adult TB # Adult Est. Cost Annual Funding 
% HIV Est. Annual Cases (All Forms) TB-HIV Cases Per Case Required to Treat  
Prevalence Adult TB Detected Under Remaining to to Treat Remaining Adult 
in Adult TB Cases that DOTS that be Treated for TB in TB Cases that 
Country Cases (2002) are HIV+ are HIV+ TB Under DOTS Adults (1) are HIV+ (2)
Botswana 79 6,527 5,731 796 $558 $444,280
Côte d’Ivoire 39 18,664 2,925 15,739 $200 $3,147,799
Ethiopia 29 52,750 22,784 29,966 $200 $5,993,272
Guyana 14 77 9 68 $200 $13,560
Haiti 28 4,513 1,392 3,121 $200 $624,170
Kenya 51 62,114 29,260 32,854 $200 $6,570,710
Mozambique 47 27,124 8,565 18,559 $200 $3,711,737
Namibia 64 6,635 5,764 871 $499 $434,664
Nigeria 27 64,107 5,167 58,941 $200 $11,788,169
Rwanda 37 8,415 1,573 6,842 $200 $1,368,420
South Africa 60 106,515 90,710 15,805 $713 $11,268,642
Tanzania 34 31,506 14,442 17,065 $200 $3,412,946
Uganda 24 14,631 6,310 8,321 $200 $1,664,214
Zambia 62 31,546 18,302 13,244 $200 $2,648,845
TOTAL 435,125 212,934 222,191 $53,091,429
** All forms includes smear-positive pulmonary, smear-negative pulmonary, and extrapulmonary new TB cases.
(1) Estimates of cost per adult TB case are based on empirical data and includes both costs for anti-TB drugs and
delivery of treatment. A cost estimate of $200 per case for 11 of the 14 countries is based on an extrapolation of
WHO data. Per case cost estimates for Botswana ($558), Namibia ($499), and South Africa ($713 for clinic-based
care only) are higher, reflecting their income status as lower middle-income countries. Costs for Botswana and
Namibia were calculated based on cost for clinic-based care in South Africa ($713/case), adjusted according to the
ratio of Gross National Income for the two countries.
(2) Formula Used: # Adult TB-HIV Cases Remaining to be Treated for TB Under DOTS x Est. Cost Per Case to
Treat TB in Adults
Data in columns 2–5 courtesy of WHO/Geneva: Global Tuberculosis Control: Surveillance, Planning, Financing.
WHO Report 2004
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TABLE 2: Estimated Additional Annual Funding Required to Treat Remaining Adult TB Cases
(All Forms**) Under DOTS (based on 2002 data)
Est. Cost Annual Funding
Est. Annual Total All Forms # Remaining Per Case Required to Treat
Population # All Forms TB Cases TB Cases to Treat All Remaining
(in of New, Active Detected Under Requiring Treatment TB in TB Cases Under
Country thousands) TB Cases DOTS Under DOTS Adults (1) DOTS (2)
Botswana 1.770 11,622 10,204 1,418 $558 $791,034
Côte d’Ivoire 16.365 67,376 10,560 56,816 $200 $11,363,103
Ethiopia 68.961 255,345 110,289 145,056 $200 $29,011,287
Guyana 0.764 879 105 774 $200 $154,818
Haiti 8.218 26,224 8,090 18,134 $200 $3,626,844
Kenya 31.540 170,213 80,183 90,030 $200 $18,005,963
Mozambique 18.537 80,893 25,544 55,349 $200 $11,069,816
Namibia 1.961 14,724 12,791 1,933 $499 $964,612
Nigeria 120.911 367,836 29,645 338,191 $200 $67,638,223
Rwanda 8.272 32,155 6,011 26,144 $200 $5,228,731
South Africa 44.759 249,660 212,616 37,044 $713 $26,412,682
Tanzania 36.276 131,566 60,306 71,260 $200 $14,251,923
Uganda 25.004 94,362 40,695 53,667 $200 $10,733,301
Zambia 10.698 71,509 41,487 30,022 $200 $6,004,327
TOTAL 394.037 1,574,363 648,526 925,837 $205,256,665
** All forms includes smear-positive pulmonary, smear-negative pulmonary, and extrapulmonary new TB cases.
(1) Estimates of cost per adult TB case are based on empirical data and includes both costs for anti-TB drugs and
delivery of treatment. A cost estimate of $200 per case for 11 of the 14 countries is based on an extrapolation of
WHO data. Per case cost estimates for Botswana ($558), Namibia ($499), and South Africa ($713 for clinic-based
care only) are higher, reflecting their income status as lower middle-income countries. Costs for Botswana and
Namibia were calculated based on cost for clinic-based care in South Africa ($713/case), adjusted according to the
ratio of Gross National Income for the two countries. 
(2) Formula Used: # Remaining TB Cases Requiring Treatment Under DOTS x Est. Cost Per Case to Treat TB in
Adults
NOTE: Annual funding required of $205.3 million includes costs required in Table 1 of $53 million.
Data in columns 2–5 courtesy of WHO/Geneva: Global Tuberculosis Control: Surveillance, Planning, Financing.
WHO Report 2004
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ANNEX 1: Country Statistics on TB, 2002
% % % TB
Est. All Forms Increase Est. # % HIV Deaths
Est. # All TB Incidence Annual All Forms New TB Cases Prevalence that are
Population Forms of   Rate (per Incidence TB in Adults in Adult HIV-
Country (in thousands) TB Cases** 100,000 pop) (1997–2002) Deaths (15-49 yrs) TB Cases infected
Botswana 1.770 11,622 657 5 1,593 71 79 63
Côte d’Ivoire 16.365 67,376 412 7 20,540 71 39 44
Ethiopia 68.961 255,345 370 7 60,938 71 29 32
Guyana 0.764 879 115 8 166 61 14 15
Haiti 8.218 26,224 319 -4 5,895 61 28 29
Kenya 31.540 170,213 540 12 41,648 71 51 53
Mozambique 18.537 80,893 436 7 23,044 71 47 51
Namibia 1.961 14,724 751 7 2,158 71 64 53
Nigeria 120.911 367,836 304 7 108,135 65 27 30
Rwanda 8.272 32,155 389 7 9,480 71 37 43
South Africa 44.759 249,660 558 7 35,497 71 60 60
Tanzania 36.276 131,566 363 3 29,789 71 34 37
Uganda 25.004 94,362 377 3 21,392 65 24 26
Zambia 10.698 71,509 668 3 16,239 71 62 55
** All forms includes smear-positive pulmonary, smear-negative pulmonary, and extrapulmonary new TB cases.
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004
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ANNEX 2: Country Trends in DOTS Coverage, Detection, and Cure
% DOTS % DOTS % DOTS 
Population Detection (2002)** Treatment Success   
Country Coverage (2002) (new smear+) (2001)** (new smear+)
Botswana 100 73 78
Côte d’Ivoire 74 25 73
Ethiopia 95 33 76
Guyana 25 11 90
Haiti 45 41 75
Kenya 100 49 80
Mozambique 100 45 77
Namibia 60 77 63
Nigeria 55 12 79
Rwanda 100 29 61 (2000 data)
South Africa 98 96 65
Tanzania 100 43 81
Uganda 100 47 56
Zambia 55 40 75
** WHO global targets for TB include 70 percent detection of new TB cases and 85 percent cure rate of those
cases by 2005. However, the ultimate goal for case detection and cure would ideally be 100 percent.
Source: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004
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first two months of the 6-9 months standard regimen; 4) uninterrupted supply of anti-TB drugs; and 5)
standardized recording and reporting system. 
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